GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Cyclically Adjusted Price-to-FCF

Telo Genomics (TSXV:TELO) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Telo Genomics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Telo Genomics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Cyclically Adjusted Price-to-FCF Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Telo Genomics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Telo Genomics's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Telo Genomics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Telo Genomics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Telo Genomics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Telo Genomics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.01/129.1809*129.1809
=-0.010

Current CPI (Mar. 2025) = 129.1809.

Telo Genomics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.026 100.500 -0.033
201509 0.000 100.421 0.000
201512 -0.057 99.947 -0.074
201603 -0.043 101.054 -0.055
201606 -0.049 102.002 -0.062
201609 -0.540 101.765 -0.685
201612 -0.201 101.449 -0.256
201703 -0.144 102.634 -0.181
201706 -0.135 103.029 -0.169
201709 -0.078 103.345 -0.098
201712 -0.152 103.345 -0.190
201803 -0.215 105.004 -0.265
201806 -0.038 105.557 -0.047
201809 -0.005 105.636 -0.006
201812 -0.007 105.399 -0.009
201903 -0.005 106.979 -0.006
201906 -0.008 107.690 -0.010
201909 -0.013 107.611 -0.016
201912 0.000 107.769 0.000
202003 -0.011 107.927 -0.013
202006 -0.013 108.401 -0.015
202009 -0.004 108.164 -0.005
202012 -0.007 108.559 -0.008
202103 -0.006 110.298 -0.007
202106 -0.006 111.720 -0.007
202109 -0.006 112.905 -0.007
202112 -0.010 113.774 -0.011
202203 -0.007 117.646 -0.008
202206 -0.008 120.806 -0.009
202209 -0.010 120.648 -0.011
202212 -0.013 120.964 -0.014
202303 -0.012 122.702 -0.013
202306 -0.011 124.203 -0.011
202309 -0.010 125.230 -0.010
202312 -0.010 125.072 -0.010
202403 -0.008 126.258 -0.008
202406 -0.007 127.522 -0.007
202409 -0.006 127.285 -0.006
202412 -0.005 127.364 -0.005
202503 -0.010 129.181 -0.010

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Telo Genomics  (TSXV:TELO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Telo Genomics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Executives
Kristan Joseph Weinberg Senior Officer
William John Meekison Director
Hugh Rogers Director

Telo Genomics Headlines

From GuruFocus